Current stock page

Financial Data

CGON Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

CGONCG Oncology Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$74.40+$4.25 (+6.06%)

Latest quote

  • Momentum
    71
  • Value
    —
  • Quality
    44
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$1.6M$1.16M$1.08M$2.32M$1.67M$0$52K$456K
Gross Profit-$1.07M-$2.77M-$1.88M-$592K$89K-$31.33M-$27.42M-$26.34M
Operating Income-$63.25M-$86.4M-$66.39M-$48.7M-$51.13M-$48.74M-$42.2M-$38.05M
Net Income-$56.89M-$79.06M-$60.2M-$41.31M-$43.81M-$41.43M-$34.45M-$31.8M
EPS-$0.64-$0.9-$0.71-$0.52-$0.57-$0.54-$0.45-$0.49
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$47.71M-$46.41M-$56.94M-$36.22M-$38.89M-$27.96M-$29.28M-$20.66M
Capital Expenditure-$1.12M-$468K-$304K-$7K-$97K-$14K-$16K-$209K
Free Cash Flow-$48.82M-$46.88M-$57.25M-$36.22M-$38.99M-$27.97M-$29.29M-$20.87M
Net Cash Provided By Operating Activities-$47.71M-$46.41M-$56.94M-$36.22M-$38.89M-$27.96M-$29.28M-$20.66M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.05B$1.09B$1.14B$791.59M$729.91M$701.45M$728.18M$754.8M
Total Debt$9.24M$8.82M$7.58M$7.02M$7.24M$994K$1.04M$238K
Cash And Cash Equivalents$28.25M$19.64M$33.7M$32.49M$45.15M$14.62M$41.47M$257.07M
Total Liabilities$55.7M$56.54M$43.48M$38.99M$42.27M$31.09M$23.42M$21.42M
Total Stockholders Equity$990.97M$1.03B$1.09B$752.6M$687.64M$670.36M$704.76M$733.38M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio6.816.415.396.044.58——2.34
P/S ratio1,072.33———————
Debt To Equity0.010.010.010.010.01000
Free Cash Flow Yield-2.80%-2.72%-2.73%-2.91%-3.72%——-2.16%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio6.816.415.396.044.58——2.34
P/S ratio1,072.33———————
Return On Equity-23.96%-21.80%-17.10%-21.39%-22.03%-19.11%-14.98%-12.00%
Debt To Equity0.010.010.010.010.01000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-26.86x
Pb6.67x
Revenue Growth Yoy-3.72%
EPS Growth Yoy-12.28%
Gross Margin-102.24%
Operating Margin-4293.53%
ROE-24.58%
ROIC-26.44%
Debt To Equity0.01
FCF Yield-2.85%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$74.40
Volume3.31M
RSI (14)61.34
MACD1.87
MACD signal0.63
MACD histogram1.24
ADX (14)24.93
SMA (50)$68.04
SMA (200)$66.68
ATR (14)$4.38
Historical volatility (annualized)75.83%
Volume (20-day average)1.21M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score59/100
Beta1.04
Annual volatility58.41%
Max Drawdown-27.41%
Sharpe Ratio1.38
VaR (95%, 1-day)-4.61%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

CGON Financial Data FAQ

What is CG Oncology Inc.'s revenue?

CG Oncology Inc.'s revenue is one of the core financial data points for CGON. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is CG Oncology Inc.'s revenue growing?

Revenue growth shows whether CG Oncology Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is CGON's EPS?

CGON's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is CG Oncology Inc.'s net income?

CG Oncology Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does CG Oncology Inc. generate?

Free cash flow shows how much cash CG Oncology Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does CG Oncology Inc. have?

Cash and debt help frame CGON's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.